Turning Evidence Generation Into a Market Access Advantage in the U.S.

Regulatory approval answers one question: is a product safe and effective enough to reach the market. It rarely answers the question that determines commercial success in the United States: will payers, health systems, and providers actually give it favorable coverage and use it. That second question is decided largely by evidence — not just the clinical trial data that supported approval, but a broader, deliberately planned body of evidence built to demonstrate value to the specific stakeholders who control access.

Companies that treat evidence generation as a post-approval afterthought consistently find themselves negotiating from a weaker position than those who planned their evidence strategy alongside their clinical development program from the start.

Why Market Access and Evidence Can't Be Separated

U.S. payers, integrated delivery networks, and pharmacy benefit managers evaluate products against comparators, cost-effectiveness expectations, and real-world outcomes data that a pivotal trial alone rarely provides. Independent value assessment organizations add another layer of scrutiny, often publishing their own cost-effectiveness analyses that influence payer negotiating positions. A product can be clinically excellent and still face restrictive coverage if the evidence package doesn't address the specific questions these stakeholders ask.

This is why evidence generation strategy has shifted from something HEOR teams manage in parallel to something that shapes trial design decisions well before a single patient is enrolled.

What Evidence Generation Means Beyond the Clinical Trial

Real-World Evidence

Registries, claims database analyses, and post-marketing observational studies fill the gap between a controlled trial population and how a product performs across the broader, more diverse patient population payers actually cover. U.S. payers increasingly expect this evidence, particularly for chronic conditions or products competing in a crowded therapeutic category.

Health-Economic and Outcomes Evidence

Cost-effectiveness models, budget-impact analyses, and comparative effectiveness data translate clinical benefit into the economic language payers use to make coverage decisions. Building these models requires access to the right comparator data early, which is why HEOR involvement during trial design — not after topline data — leads to stronger evidence packages.

Patient-Reported and Humanistic Outcomes

Increasingly, payers and providers want evidence of how a product affects daily functioning and quality of life, not just clinical endpoints. Building validated patient-reported outcome measures into trial design supports both regulatory labeling claims and access negotiations later.

Aligning Evidence Strategy with U.S. Payer Expectations

Different stakeholders weigh evidence differently. Commercial payers and PBMs often prioritize budget impact and comparative cost-effectiveness. Health systems and integrated delivery networks may weight real-world safety and total cost of care more heavily. Independent value-assessment bodies apply their own methodologies, and understanding how a product is likely to be evaluated by these groups — before pivotal data is locked — allows sponsors to generate the specific evidence types most likely to influence each audience.

Value-based and outcomes-based contracting arrangements, increasingly common in specialty and high-cost therapeutic categories, add another layer: these agreements typically require ongoing real-world data collection to track whether contracted outcomes are actually being achieved, which means evidence generation doesn't end at launch — it becomes a continuous commercial function.

Building an Evidence Plan Early, Not Retroactively

The organizations that navigate U.S. market access most effectively typically build an integrated evidence plan during Phase 2 or early Phase 3, mapping out which stakeholders need which evidence types and by when. This allows real-world evidence studies, health-economic models, and patient-reported outcome instruments to be designed and initiated well before launch, rather than commissioned reactively after a payer pushback reveals a gap in the evidence package.

Common Pitfalls

The most frequent mistake is treating evidence generation as a single deliverable — one HEOR dossier — rather than an ongoing, multi-audience strategy. A second common pitfall is failing to align evidence generation timing with actual payer decision cycles, resulting in critical real-world data that isn't available until well after the coverage decisions it was meant to inform. Finally, many organizations underinvest in stakeholder-specific evidence, producing generic clinical and economic data that doesn't directly answer the questions a specific payer or health system committee will ask. This can ultimately limit the ability to demonstrate value access across different stakeholders.

Practical Steps for Building an Evidence Strategy

Start by mapping the specific evidence expectations of the payers, health systems, and value assessment bodies most relevant to the therapeutic category. Build health-economic modeling capability into the development timeline early enough to influence trial endpoint selection. Plan for real-world evidence generation to continue well past launch, particularly if value-based contracting is a likely commercial strategy. And treat evidence generation as a cross-functional responsibility spanning clinical development, HEOR, medical affairs, and market access — not a single team's deliverable handed off at the end.

Evidence generation done well doesn't just support a value story — it becomes the value story, built from the ground up to answer the specific questions U.S. payers and health systems are actually going to ask.

FAQs / Q&A

Q1. What's the difference between market access and evidence generation? Market access refers to the overall strategy for securing favorable coverage, reimbursement, and formulary placement. Evidence generation is the process of producing the clinical, economic, and real-world data that supports that access strategy — the two work together, with evidence generation providing the substance behind market access negotiations.

Q2. Why isn't clinical trial data alone enough for U.S. market access? Payers and health systems typically want to see how a product performs in real-world, more diverse populations, along with cost-effectiveness and comparative data that a pivotal trial — designed primarily for regulatory approval — often doesn't fully address.

Q3. When should evidence generation planning start? Ideally during Phase 2 or early Phase 3 development, so that real-world evidence studies, health-economic models, and patient-reported outcome measures can be designed and initiated well before launch rather than commissioned reactively.

Q4. What role does real-world evidence play after a product launches? Post-launch real-world evidence supports ongoing payer negotiations, value-based contracting commitments, and label expansion efforts, making evidence generation a continuous function rather than a one-time pre-launch deliverable.

Q5. How do independent value assessment organizations affect U.S. market access? Organizations that publish independent cost-effectiveness analyses can meaningfully influence payer negotiating positions, which is why many sponsors now build evidence generation strategies that anticipate how these groups are likely to evaluate their product.